Asherman Therapy

Asherman Therapeutics is a clinical-stage biotechnology company dedicated to developing regenerative medicine solutions for Asherman's Syndrome and other endometrial pathologies. The company's lead program, AT-01, utilizes autologous bone marrow-derived stem cell (BMDSC) therapy to restore endometrial function and improve fertility outcomes in women with severe intrauterine adhesions. By leveraging advanced cell-based technologies, Asherman Therapeutics aims to address significant unmet needs in reproductive health and women's medicine. The company was founded by Dr. Carlos Simon, a world-renowned expert in reproductive medicine and human endometrial receptivity. Their approach focuses on the mobilization and transplantation of specific stem cell populations to promote tissue repair and functional recovery of the uterine lining.